We are live on ! Find out more
OREX

Orexigen Therapeutics
OREX

Delisted

OREX was delisted on the 3rd of April, 2018.

42 hedge funds and large institutions have $8.82M invested in Orexigen Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital inflows, than outflows

Capital inflows: $3.49M | Capital outflows: $1.94M

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

4.2% more ownership

Funds ownership: 37.23% → 41.43% (+4.2%)

1% more call options, than puts

Call options by funds: $394K | Put options by funds: $390K

0% more funds holding

Funds holding: 42 → 42 (0)

9% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 11

Holders
42
Holders Change
–
Holders Change %
0%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
11
Closed
8
Calls
$394K
Puts
$390K
Net Calls
+$4K
Net Calls Change
-$114K

OREX Hedge Fund Activity: Q4 2017 in Review

42 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics (OREX) for Q4 2017, worth a combined $8.82M — down 27% from $12.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OREX positions and 8 closed out — a net gain of 1 holder — while 10 added to existing stakes and 11 trimmed.

The largest buyer was GLG LLC, opening a new position worth an estimated $2.48M. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $1.11M sold.

  • 42 institutional investors held Orexigen Therapeutics (OREX) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $8.82M of Orexigen Therapeutics stock for Q4 2017, down 27% quarter-over-quarter.
  • 9 funds opened new Orexigen Therapeutics positions in Q4 2017 and 8 closed out, a net change of +1 holder.
  • The largest Orexigen Therapeutics buyer in Q4 2017 was GLG LLC, an estimated $2.48M added.
  • The largest Orexigen Therapeutics seller in Q4 2017 was Foresite Capital Management II, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2017.